Cardio-Oncology in Japan

Cardio-oncology for the 21st century: introduction.

Cardio-oncology: it takes two to translate.

As an emerging discipline focused on the cardiovascular care of cancer patients, cardio-oncology represents a novel platform for translational investigations. Toxic effects on the heart and vasculature caused by targeted cancer therapies can reveal insights into the biology of cardiovascular disease in humans. This phenomenon was first observed with trastuzumab, a monoclonal antibody that targe...

Cardio-Oncology: mechanisms of cardiovascular toxicity

The therapeutic options available to treat a wide range of malignancies are rapidly increasing. At the same time, the population being treated is aging with more cardiovascular risk factors, comorbid conditions, and associated poor cardiac reserve. Both traditional chemotherapeutic agents (for example, anthracyclines) and newer therapies (for example, targeted tyrosine kinase inhibitors and imm...

Cardio-oncology: a new medical issue

Due to the increasing number of long-term cancer survivors, the ageing of the population, as well as the increased incidence and prevalence of oncologic and cardiovascular diseases, the number of patients presenting oncologic and cardiologic co-morbidities are increasing. Accordingly, there is a rapidly growing need for a comprehensive and proficient management of patients in whom the two co-mo...

Perspectives in Pharmacology Pharmacological Foundations of Cardio-Oncology

Anthracyclines and many other antitumor drugs induce cardiotoxicity that occurs “on treatment” or long after completing chemotherapy. Dose reductions limit the incidence of early cardiac events but not that of delayed sequelae, possibly indicating that any dose level of antitumor drugs would prime the heart to damage from sequential stressors. Drugs targeted at tumor-specific moieties raised ho...